PHARMAS CRUSHED BY THE NOVO SPELL
02/01/25 -"Pharmas closed the year with a dreadful performance, itself the reflection of dashed excessive hopes for GLP-1 developments. The unwarranted Novo Nordisk collapse on 19-12 on a marginal miss in its ..."
Pages
54
Language
English
Published on
02/01/25
You may also be interested by these reports :
16/09/26
Reading European equities earnings dynamic, i.e. revisions, remains a brain torturing exercise for anyone wondering where the 2026 earnings growth at ...
15/09/26
ENGIE has been one of the best performers across our utilities coverage since the 2022 energy crisis, and more strikingly, the run accelerated ...
10/09/26
Europe’s empty tanks, how to trade a winter with no safety net?
10/09/26
We have updated our estimates for the Loviisa PPA. With no price disclosed, we reverse-engineered it from management’s guidance of a c.1.4pp uplift ...